Biomea Fusion Inc Asset Resilience Ratio
Biomea Fusion Inc asset resilience ratio. Biomea Fusion Inc (BMEA) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Biomea Fusion Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biomea Fusion Inc (2020–2023)
Asset resilience ratio of Biomea Fusion Inc from 2020 to 2023. This chart shows how Biomea Fusion Inc's Asset Resilience Ratio has changed over time. Read BMEA total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biomea Fusion Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BMEA current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Biomea Fusion Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Biomea Fusion Inc Industry Peers by Asset Resilience Ratio
Compare Biomea Fusion Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Biomea Fusion Inc Asset Resilience Ratio by Year (2020–2023)
Biomea Fusion Inc asset resilience ratio by year from 2020 to 2023. The table below shows the annual Asset Resilience Ratio data for Biomea Fusion Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $199.93 Million | -- |
| 2022-12-31 | 0.89% | $1.15 Million | $129.31 Million | -14.07pp |
| 2021-12-31 | 14.96% | $27.78 Million | $185.71 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $62.53 Million | -- |
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase I… Read more